Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients.

IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Daniela Mocan, Maria Puschita, Diana Lungeanu, Adina Pop-Moldovan, Luminita Pilat, Dan Darabantiu, Radu Jipa, Radu Ioan Lala
{"title":"Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients.","authors":"Daniela Mocan, Maria Puschita, Diana Lungeanu, Adina Pop-Moldovan, Luminita Pilat, Dan Darabantiu, Radu Jipa, Radu Ioan Lala","doi":"10.1002/ehf2.15356","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>We aim to assess the efficacy of congestion relief and safety associated with adding SGLT2i (viz., dapagliflozin 10 mg) to intravenous loop diuretics within 24 h of hospital presentation in patients with acute heart failure (AHF).</p><p><strong>Methods and results: </strong>A single-centre open-label clinical research study enrolled 98 patients admitted with an episode of AHF who were randomized into two groups: (a) receiving SGLT2i once daily in addition to structured intravenous furosemide therapy; (b) receiving structured intravenous furosemide therapy alone. In-hospital congestion relief was evaluated by body weight change, EVEREST score, lung ultrasound B-lines, inferior vena cava ultrasound measurement, NT-proBNP and CD146. Safety was assessed by changes in renal function and serum electrolyte abnormalities. Secondary endpoints included diuresis and natriuresis, hospital care indices and echocardiographic changes in cardiac function at 1-month. ANCOVA analysis was performed to adjust for imbalance between the two groups regarding chronic kidney disease status and baseline values. The analysis followed an intention-to-treat approach. The mean age ± standard deviation in the SGLT2i and control group was 63.63 ± 10.95 years and 65.31 ± 10.82 years, respectively, with 40/49 and 42/49 males. No death occurred in hospital; 1/49 and 2/49 deaths at 30 days were recorded. The adjusted mean change ± standard error (SE) in body weight was -4.90 ± 0.93 kg versus -4.28 ± 0.81 kg in the SGLT2i and control group, respectively. The adjusted mean change ± SE in B-lines at discharge and at 1 month was -19.93 ± 0.87 versus -18.64 ± 0.79 (P = 0.227) and -19.65 ± 1.54 versus -14.82 ± 1.43 (P = 0.012), respectively. The proportion of worsening renal function was 15/49 and 6/47 (P = 0.048) in the respective treatment groups (SGLT2i and control). The adjusted mean ± SE of 24-h urinary Na was 248.03 ± 23.69 mmol/day versus 173.83 ± 20.76 mmol/day (P = 0.009). One-month changes in ultrasound parameters were significantly improved in the SGLT2i group, with median (inter-quartile range) values of left ventricular ejection fraction and end-diastolic volume equal to 5% (0.35% to 11.5%) versus 0 (-1% to +5%) and -6.5 mL (-27.5 to +3) versus 4 mL (-11.5 to +10), respectively.</p><p><strong>Conclusions: </strong>Early initiation of SGLT2i administration in addition to intravenous loop diuretics in patients with AHF would optimize congestion relief and improve clinical outcomes.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15356","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: We aim to assess the efficacy of congestion relief and safety associated with adding SGLT2i (viz., dapagliflozin 10 mg) to intravenous loop diuretics within 24 h of hospital presentation in patients with acute heart failure (AHF).

Methods and results: A single-centre open-label clinical research study enrolled 98 patients admitted with an episode of AHF who were randomized into two groups: (a) receiving SGLT2i once daily in addition to structured intravenous furosemide therapy; (b) receiving structured intravenous furosemide therapy alone. In-hospital congestion relief was evaluated by body weight change, EVEREST score, lung ultrasound B-lines, inferior vena cava ultrasound measurement, NT-proBNP and CD146. Safety was assessed by changes in renal function and serum electrolyte abnormalities. Secondary endpoints included diuresis and natriuresis, hospital care indices and echocardiographic changes in cardiac function at 1-month. ANCOVA analysis was performed to adjust for imbalance between the two groups regarding chronic kidney disease status and baseline values. The analysis followed an intention-to-treat approach. The mean age ± standard deviation in the SGLT2i and control group was 63.63 ± 10.95 years and 65.31 ± 10.82 years, respectively, with 40/49 and 42/49 males. No death occurred in hospital; 1/49 and 2/49 deaths at 30 days were recorded. The adjusted mean change ± standard error (SE) in body weight was -4.90 ± 0.93 kg versus -4.28 ± 0.81 kg in the SGLT2i and control group, respectively. The adjusted mean change ± SE in B-lines at discharge and at 1 month was -19.93 ± 0.87 versus -18.64 ± 0.79 (P = 0.227) and -19.65 ± 1.54 versus -14.82 ± 1.43 (P = 0.012), respectively. The proportion of worsening renal function was 15/49 and 6/47 (P = 0.048) in the respective treatment groups (SGLT2i and control). The adjusted mean ± SE of 24-h urinary Na was 248.03 ± 23.69 mmol/day versus 173.83 ± 20.76 mmol/day (P = 0.009). One-month changes in ultrasound parameters were significantly improved in the SGLT2i group, with median (inter-quartile range) values of left ventricular ejection fraction and end-diastolic volume equal to 5% (0.35% to 11.5%) versus 0 (-1% to +5%) and -6.5 mL (-27.5 to +3) versus 4 mL (-11.5 to +10), respectively.

Conclusions: Early initiation of SGLT2i administration in addition to intravenous loop diuretics in patients with AHF would optimize congestion relief and improve clinical outcomes.

急性心力衰竭患者静脉袢利尿剂加用达格列净缓解肺充血。
目的:我们旨在评估急性心力衰竭(AHF)患者入院后24小时内将SGLT2i(即达格列净10mg)加入静脉循环利尿剂的充血缓解效果和安全性。方法和结果:一项单中心开放标签临床研究纳入了98例AHF发作患者,他们被随机分为两组:(A)在结构化静脉速尿治疗的基础上,每天接受一次SGLT2i治疗;(b)单独接受有组织的静脉速尿治疗。通过体重变化、EVEREST评分、肺超声b线、下腔静脉超声测量、NT-proBNP和CD146评估院内充血缓解情况。通过肾功能变化和血清电解质异常来评估安全性。次要终点包括利尿和尿钠、医院护理指数和1个月时心功能的超声心动图变化。进行ANCOVA分析以调整两组之间关于慢性肾脏疾病状态和基线值的不平衡。分析遵循意向治疗方法。SGLT2i组和对照组的平均年龄±标准差分别为63.63±10.95岁和65.31±10.82岁,男性分别为40/49和42/49。医院内无死亡病例;记录了30天内1/49和2/49的死亡。SGLT2i组和对照组的体重调整平均变化±标准误差(SE)分别为-4.90±0.93 kg和-4.28±0.81 kg。出院时和1个月时b线校正平均变化±SE分别为-19.93±0.87对-18.64±0.79 (P = 0.227)和-19.65±1.54对-14.82±1.43 (P = 0.012)。各治疗组(SGLT2i和对照组)肾功能恶化的比例分别为15/49和6/47 (P = 0.048)。24h尿钠校正均数±SE分别为248.03±23.69 mmol/day和173.83±20.76 mmol/day (P = 0.009)。SGLT2i组超声参数的一个月变化显著改善,左室射血分数和舒张末期容积的中位数(四分位数范围)分别为5%(0.35%至11.5%)和-6.5 mL(-27.5至+3),分别为0(-1%至+5%)和4 mL(-11.5至+10)。结论:AHF患者在静脉循环利尿剂的基础上早期给予SGLT2i将优化充血缓解并改善临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信